1:2 Bonus, 25% Dividend Declared: Pharma Co Posts 35.93% Net, Shares Rise 124% In 6-Months

Small cap Pharmaceutical sector company Gujarat Themis Biosyn Ltd today declared a jump of 35.93% in its net profit to Rs 15.89 crore for the quarter ended March 2024 as compared to Rs 11.69 crore net profit reported in the corresponding quarter of last year. The company recommended Re 0.25 per share dividend and approved 1:2 bonus issue. Gujarat Themis Biosyn Ltd share gained 2.95% in trade today to Rs 414.15 per share. Gujarat Themis Biosyn shares rallied 161% in last 1-year. Its market capitalisation is Rs 3008.53 crore. More details below:

Gujarat Themis Recommends Dividend: The exchange filing of the company stated, "recommended dividend for Financial Year ended 31 st March, 2024 Rs. 0.25/ · i.e.@ 25% per- equity share having face value of Re.1 /· aggregating to Rs. 1,81 ,60,877.50/ ·. The payment is subject to the appro·val of shareholders at the ensuing Annual General Meeting."

Gujarat Themis Declares Bonus Issue: As per the BSE filing of Gujarat Themis dated May 14, 2024, "Issue of 1 (One) Bonus Shares for every 2 (Two) Equity Shares held by the Equity Shareholders of the Company as on 'Record Date'. The Bonus Issue of Equity Shares is subject to the approval of the shareholders and other applicable statutory and regulatory approvals, as may be required. The Company will intimate the 'Record Date' for determining eligible Shareholders entitled to receive bonus shares, in due course _of time."

Gujarat Themis Biosyn Q4 Results: The pharma company's sales zoomed 52.27% to Rs 42.01 crore for the March 2024 quarter as against Rs 27.59 crore declared in the March 2023 quarter. For the whole year, its net profit rose 2.05% to Rs 59.16 crore for the year ended March 2024 as compared to Rs 57.97 crore reported in the preceding year ended March 2023. Sales zoomed 14.44% to Rs 169.82 crore for the year ended March 2024 as against Rs 148.39 crore in March 2023.

Gujarat Themis Biosyn Share Performance: The 52-week high price of Gujarat Themis Biosyn share on BSE is Rs 435.00 per share (as on 06/05/2024) and 52-week low price is Rs 145.80 per share (as on 26/05/2023). Gujarat Themis Biosyn share offered return of 443% in last 2-years, rallied 678% in last 3-years, and zoomed 5076% in last 5-years.

Gujarat Themis Biosyn Shareholding: Promoters holding remains unchanged at 70.86% in March 2024 quarter. Number of FII/FPI investors increased from 10 to 13 in March 2024 quarter. Mutual Funds have increased holdings from 0.02% to 0.80% in Mar 2024 quarter. Number of MF schemes increased from 3 to 4 in Mar 2024 quarter.

Gujarat Themis About: It was incorporated in 1981 as a joint sector company with GIIC Ltd and Chemosyn (P) Ltd. The company started production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan's know-how, GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin, according to its official website.

Disclaimer: The stock just highlights the dividend, Q4 results, bonus issue is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.